Tag: gastric cancer

ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer

businessnewstoday- June 27, 2023

ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone with its flagship drug candidate evorpacept securing ... Read More

ALX Oncology’s evorpacept gets FDA ODD for gastric cancer and gastroesophageal junction cancer

pallavi123- January 30, 2022

ALX Oncology said that its CD47 blocker evorpacept has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) in gastric cancer ... Read More

DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response

pallavi123- September 18, 2021

AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric ... Read More

Ambrx’s ARX788 gets FDA orphan drug status for gastric cancer treatment

pallavi123- April 24, 2021

Ambrx has announced that its antibody drug conjugate (ADC) ARX788 has been granted orphan drug designation by the US Food and Drug Administration for the ... Read More

Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab

pallavi123- March 4, 2021

Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add ... Read More

Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer

pharmanewsdaily- June 12, 2020

US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of ... Read More

Everything you need to know about warning signs of stomach cancer

pharmanewsdaily- January 29, 2019

It is good to know about the warning signs of stomach cancer as the stomach cancer may go undetected for years. Stomach cancer is also ... Read More

Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

pharmanewsdaily- December 11, 2017

Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of ... Read More